
The public body responsible for providing guidance and advice for England and Wales, the National Institute for Health and Care Excellence (NICE), has announced in a press release that it does not recommend Leo Pharma’s Adtralza (tralokinumab) as a treatment for atopic dermatitis.
The Danish pharmaceutical firm’s drug was approved in Europe around a year ago, but NICE now questions whether Adtralza works better than other drugs against the disease also known as atopic eczema.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app